scPharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to include treatment of edema in patients with chronic kidney disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH: